Next Science 将来の成長

Future 基準チェック /26

Next Scienceは、47.6%と30.6%でそれぞれ年率47.6%で利益と収益が成長すると予測される一方、EPSはgrowで58.9%年率。

主要情報

47.6%

収益成長率

58.9%

EPS成長率

Medical Equipment 収益成長	16.5%
収益成長率	30.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	21 Oct 2024

今後の成長に関する最新情報

Recent updates

Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Jan 22

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper

Oct 22

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce

Jul 26

It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks

Jun 08

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Apr 16

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Mar 06

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Dec 26

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Oct 26

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

May 13

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Feb 03

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Jan 25

What Type Of Returns Would Next Science's(ASX:NXS) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 23

業績と収益の成長予測

ASX:NXS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	50	-2	N/A	N/A	1
12/31/2025	39	-9	N/A	N/A	1
12/31/2024	28	-11	N/A	N/A	1
6/30/2024	23	-14	-13	-12	N/A
3/31/2024	23	-15	-14	-14	N/A
12/31/2023	22	-16	-16	-15	N/A
9/30/2023	19	-15	-15	-14	N/A
6/30/2023	16	-15	-14	-13	N/A
3/31/2023	14	-14	-13	-13	N/A
12/31/2022	12	-13	-12	-12	N/A
9/30/2022	11	-12	-12	-12	N/A
6/30/2022	10	-12	-12	-11	N/A
3/31/2022	10	-11	-10	-10	N/A
12/31/2021	9	-9	-9	-8	N/A
9/30/2021	8	-9	-10	-9	N/A
6/30/2021	6	-9	-11	-10	N/A
3/31/2021	5	-11	-12	-11	N/A
12/31/2020	3	-12	-13	-12	N/A
9/30/2020	3	-12	-12	-11	N/A
6/30/2020	3	-13	-11	-10	N/A
3/31/2020	3	-13	-13	-11	N/A
12/31/2019	4	-14	-14	-12	N/A
9/30/2019	4	-15	-14	-13	N/A
6/30/2019	4	-16	-15	-14	N/A
3/31/2019	4	-15	-14	-13	N/A
12/31/2018	3	-14	-13	-12	N/A
12/31/2017	4	-2	N/A	N/A	N/A
12/31/2016	1	-3	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NXS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NXS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: NXS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NXSの収益 ( 30.6% ) Australian市場 ( 6% ) よりも速いペースで成長すると予測されています。

高い収益成長: NXSの収益 ( 30.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NXSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/02/07 12:33
終値	2025/02/07 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Next Science Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。3

アナリスト	機関
Martyn Jacobs	Canaccord Genuity
Dr Benson	Wilsons Advisory and Stockbroking Ltd.
Dr Storey	Wilsons Advisory and Stockbroking Ltd.

Next Science 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 11%

Consensus revenue estimates decrease by 10%

Consensus revenue estimates increase by 26%, EPS downgraded

Consensus EPS estimates fall from profit to US$0.051 loss, revenue upgraded

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Recent updates

Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025

Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025

Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former Employee

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper

Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024

Consensus EPS estimates fall by 11%

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce

Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024

Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024

It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks

New minor risk - Share price stability

Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Next Science Limited, Annual General Meeting, May 03, 2024

Full year 2023 earnings released: US$0.069 loss per share (vs US$0.06 loss in FY 2022)

Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Consensus revenue estimates decrease by 10%

Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director

Consensus revenue estimates increase by 26%, EPS downgraded

New minor risk - Shareholder dilution

First half 2023 earnings released: US$0.04 loss per share (vs US$0.032 loss in 1H 2022)

New minor risk - Financial data availability

Next Science Limited Announces Board Changes

Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer

New minor risk - Share price stability

Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products

Next Science Limited Announces Executive Changes

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

Founder & CTO recently sold AU$1.5m worth of stock

Consensus EPS estimates fall from profit to US$0.051 loss, revenue upgraded

Full year 2022 earnings released: US$0.06 loss per share (vs US$0.047 loss in FY 2021)

Next Science Limited, Annual General Meeting, May 26, 2023

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Forecast breakeven date pushed back to 2024

Next Science Limited announced that it expects to receive AUD 10 million in funding from Walker Group Holdings Pty Limited

Insufficient new directors

Next Science Limited Announces the Launch of Topical Collagen Products

Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE

First half 2022 earnings released: US$0.032 loss per share (vs US$0.021 loss in 1H 2021)

Forecast breakeven date pushed back to 2024

Next Science Limited to Report First Half, 2022 Results on Aug 25, 2022

Consensus forecasts updated

Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer

Insufficient new directors

MD, CEO & Executive Director recently sold AU$123k worth of stock

Next Science Limited, Annual General Meeting, May 27, 2022

Forecast to breakeven in 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Insufficient new directors

Founder & CTO recently sold AU$8.6m worth of stock

First half 2021 earnings released: US$0.021 loss per share (vs US$0.037 loss in 1H 2020)

Next Science Limited Agrees to Open Negotiations with Zimmer, Inc

Next Science Limited Provides Revenue Guidance for the First Half of 2021

Next Science Limited Receives Approval for BlastX from Therapeutic Goods Administration for Sale in Australia

Independent Non-Executive Chairman George Savvides has left the company

Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Next Science Limited Announces XPerience No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Independent Non-Executive Director recently sold AU$564k worth of stock

MD, CEO & Executive Director exercised options to buy AU$2.5m worth of stock.

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)

Next Science Limited (ASX:NXS) Is Expected To Breakeven In The Near Future

Next Science Limited, Annual General Meeting, May 05, 2021

Analysts update estimates